Danish-based pharmaceutical company Alk’s house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet Acarizax has secured approval for expansion in 12 European countries.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The product can be used in adolescent patients with HDM-induced allergic rhinitis.

The approval covers patients aged between 12 and 17 and is based upon data from clinical trials conducted in Japan and North America as part of the worldwide Acarizax clinical development programme in February this year.

This data led the global initiative for asthma (GINA), for the first time, to add allergy immunotherapy as a treatment option in its global strategy for asthma management and prevention.

See Also:

Alk research and development executive vice-president Henrik Jacobi said: “This expanded approval is important for patients and important to Alk’s strategy for Acarizax.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"This expanded approval is important for patients and important to Alk’s strategy for Acarizax."

“For patients, it means there can now be an earlier intervention to treat a condition that has far-reaching consequences for teenagers whose sleep, education and social lives are blighted by house dust mite allergy.”

Following the latest approval, the tablet can now be used in adolescents in Austria, the Czech Republic, Denmark, Finland, Italy, the Netherlands, Norway, Poland, Sweden, Slovakia, and the key European markets of France and Germany.

Initially, when Acarizax gained European approval for use in adults in 2015, it also became the first SLIT product to be approved for use in allergic asthma.

At present, the drug is approved in 17 countries worldwide and launched in nine countries.

Image: Alk’s production facilities in Hørsholm. Photo: courtesy of ALK-Abelló A/S.